ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2041

Pregnancy Outcomes In Women Exposed To Golimumab

Amy G. Lau1, Michael Clark1, Diane D. Harrison1, Anja Geldhof2, Riikka Nissinen2 and Marilyn Sanders1, 1Janssen Research & Development, LLC., Horsham, PA, 2Janssen Biologics Europe, Leiden, Netherlands

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), Biologics, pregnancy, psoriatic arthritis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases II: Miscellaneous Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatologic conditions and inflammatory bowel disease can affect women of childbearing potential. Golimumab (GLM) is approved for rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and ulcerative colitis (UC). GLM should be used during pregnancy only if clearly needed. For RA and some PsA patients, GLM is administered with methotrexate (MTX), an agent with teratogenic and abortifacient properties. To characterize pregnancy outcomes in patients treated with GLM, data obtained from maternal exposure to GLM are presented.  

 

Methods: This dataset includes individual patient cases reported to the manufacturer through 06 April 2013. Cases retrieved included prospectively reported (ie, pregnancy outcome not known when first reported) and retrospectively reported (ie, pregnancy outcome known when first reported) maternal exposures to GLM for all approved indications during pregnancy or within 2 months prior to conception, and a reported pregnancy outcome. Cases originated from various sources, including spontaneous reporting, clinical studies, and registries.

 

Results : Forty pregnancy reports with reported outcomes (24 RA; 1 PsA; 5 AS; 10 UC) were identified (32 prospective, 8 retrospective). Of these 40 pregnancies, 30 were reported from clinical trials. Average maternal age was 33.2 years. Of the 40 pregnancy reports, 19 (47.5%) resulted in live births, 13 (32.5%) resulted in spontaneous abortion, 7 (17.5%) resulted in induced abortion, and 1 (2.5%) resulted in ectopic pregnancy (Table). One spontaneous prospectively reported patient case (2.5%) reported a congenital anomaly with an unspecified birth defect resulting in intrauterine death and an induced abortion. Of the 13 reports with a pregnancy outcome of spontaneous abortion, 4 (30.8%) patients received MTX concomitantly with GLM, as compared to 3 out of 19 (15.8%) reports in the GLM exposed pregnancies resulting in live births. In the 1 pregnancy with a congenital anomaly, the patient had used MTX, but the timing of MTX use was not available.

 

Conclusion: This review of pregnancy outcomes after GLM exposure in utero reported 1 congenital anomaly in a small number (40) of pregnancies; the rate of congenital anomalies was consistent with the background rate. Out of the 40 pregnancies, 32.5% reported spontaneous abortions. Of those pregnancies, 30.8% of the patients received MTX, an agent which is contraindicated in pregnant women due to its teratogenic and aborifacient properties. Limitations of this analysis included the lack of a direct comparison group, the variable amount of data available in the reports, and the possible bias towards reporting more negative outcomes in retrospective cases.

 

 

Table:    Summary of pregnancy outcomes in patients treated with GLM for RA, PsA, AS, and UC

 

Pregnancy Outcome

RA, PsA, AS, and UC Patient Cases

 

Count (%)

Congenital Anomaly

MTXa

Live birth

19 (47.5)

0

3

Spontaneous abortion

13 (32.5)

0

4

Elective/Induced abortion

6 (15.0)

1

2

Abortion planned

1 (2.5)

0

0

Ectopic pregnancy

1 (2.5)

0

1

Total

40

1

10

a: Patient received MTX at the time of conception/during pregnancy.

KEY: AS=Ankylosing spondylitis; MTX=Methotrexate; PsA=Psoriatric arthritis; RA=Rheumatoid arthritis; UC=Ulcerative colitis.

 

 

 

 


Disclosure:

A. G. Lau,

Janssen Research & Development, LLC.,

3;

M. Clark,

Janssen Research & Development, LLC.,

3;

D. D. Harrison,

Janssen Research & Development, LLC.,

3;

A. Geldhof,

Janssen Biologics Europe,

3;

R. Nissinen,

Janssen Biologics Europe,

3;

M. Sanders,

Janssen Research & Development, LLC.,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pregnancy-outcomes-in-women-exposed-to-golimumab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology